Sign in
Taking people in United StatesPhase 2

Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance

Key facts

Who runs it
Fred Hutchinson Cancer Center
Where
Seattle, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
22 Jan 2026
Expected to end
1 May 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Rifaximin
  • Biospecimen Collection
Record updated
17 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants
  • Clinical diagnosis of IgG/IgA (non-IgM) monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014). It is recognized that not all patients with clinical diagnosis of MGUS undergo bone marrow biopsy. Bone marrow biopsy confirmation will not be required if not clinically indicated per treating provider
  • Agree to use adequate contraception; For women of child-bearing potential: prior to study entry and for the duration of study participation; For men: prior to study entry, for the duration of study participation, and one month after completion of rifaximin administration (for men)
  • No antibiotic use in the preceding 2 weeks

Who cannot take part

  • Participants who are receiving other investigational agents
  • Another concurrent malignancy requiring active therapy
  • Known hypersensitivity to rifaximin
  • Pregnant women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in United States.

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Madhav Dhodapkar, MBBSTaking people

About the trial

What the trial wants to find out

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG/IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgG/IgA MGUS.

The 2 groups in the trial

  • Arm A (Rifaximin)Treatment being tested

    Patients receive rifaximin orally (PO) three times daily (TID) for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

    Treatment: Rifaximin and Biospecimen Collection

  • Arm B (No intervention)Other group

    Patients undergo blood sample collection throughout the study.

    Treatment: Biospecimen Collection

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Rifaximin Versus No Intervention in Patients With IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
Criteria questions
Built from NCT07209371, who can take part
Record updated
17 August 2026